Evidence map›Paper›PMID 38157111›Full record

Trial reportMedical oncology (Northwood, London, England)2023

PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.

Giulio Francolini, Angelo Porreca, Gaetano Facchini, Daniele Santini, Alessio Bruni, Nicola Simoni, Marco Trovò, Mattia Falchetto Osti, Giuseppe Fornarini, Michele Sisani and 7 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Giulio FrancoliniRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. francolinigiulio@gmail.com.ORCID http://orcid.org/0000-0002-1784-7203
Angelo PorrecaDepartment of Oncological Urology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Gaetano FacchiniMedical Oncology Unit, SM Delle Grazie Hospital, Naples, Italy.
Daniele SantiniOncologia Medica A, Policlinico Umberto 1, La Sapienza Università Di Roma, Rome, Italy.
Alessio BruniRadiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Nicola SimoniRadiotherapy Unit, Azienda Ospedaliera Universitaria, Parma, Italy.
Marco TrovòDepartment of Radiation Oncology, University General Hospital, Udine, Italy.
Mattia Falchetto OstiDepartment of Radiation Oncology, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Michele SisaniMedical Oncology, Usl Toscana Sud est, Arezzo, Italy.
Vanessa Di CataldoRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Beatrice DettiRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Pietro GarlattiRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Niccolò BertiniDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Sergio SerniUnit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy.
Andrea MinerviniUnit of Urological Oncologic Minimally Invasive Robotic Surgery and Andrology, Careggi Hospital, University of Florence, Florence, Italy.
Lorenzo LiviDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · ITAzienda Usl 8 Arezzo · ITIstituto Oncologico Veneto · ITOspedale Madonna Delle Grazie · ITOspedale Policlinico San Martino · ITPoliclinico Umberto I · ITSapienza University of Rome · ITUniversity of Modena and Reggio Emilia · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Earlier treatment intensification with systemic potent androgen receptor inhibition has been shown to improve clinical outcomes in metastatic hormone sensitive prostate cancer. Nonetheless, oligometastatic patients may benefit from local treatment approaches such as stereotactic body radiotherapy (SBRT). Aiming to explore the benefit of SBRT in this scenario, we designed this trial to specifically test the hypothesis that SBRT will improve clinical outcomes in select population affected by metachronous oligometastatic HSPC treated with androgen deprivation therapy + apalutamide. Enrolled patients will be randomized to receive the standard systemic treatment alone or in combination with SBRT on all metastatic sites of disease. Here we report the protocol design and an overview of the ongoing trials testing different integration strategies between RT and systemic therapies.

Indexed as

Prostatic NeoplasmsRadiosurgeryAndrogen AntagonistsAndrogensHumansMaleThiohydantoinsAndrogen AntagonistsAndrogensapalutamideThiohydantoinsApalutamideMetastatic hormone sensitive prostate cancerStereotactic body radiotherapy

Identifiers

PMID38157111
OpenAlexW4390412092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.